Compiled by Cari Kraft, Jacobs Management Group, Inc.
Orphan drug sales to become 1/5 of the market.
Worldwide Orphan Drug sales are expected to grow to $178b (up from $97b in 2014) in 2020 making up 20% of the total drug market.
Source: Worldwide Orphan Drug Sales (2000-2020), Evaluatepharma, 30 September 2015
$48b dollars in drugs will go.
Drugs that are expected to go the 2015 off-patent cliff will contribute to just under $48B for pharmaceutical revenue. However, the FDA approved 44 drugs in total to be launched in which $58b are expected to counter that loss.
Source: Patent Cliff II is here, But do Pharmacy Chains Need to Worry?, Trefis®, Feb 24, 2015
Pharma’s average cost to develop 1 drug.
Only 11.8% of products that enter clinical testing reach regulatory approval. If a new drug does make it through to market approval, the total cost through R&D, testing and failures is $2.6b
Source: Innovation in Drug Development Process Remains a Key Challenge, Tufts Center for the Study of Drug Development, October 20, 2015
The FDA approves 50% more PMA’s in 2015 vs 2014
FDA approved 30 new PMAs in 2015, a 50% increase over the same time period in 2014.The number of first time PMAs and HDE increased 43% in 2014 to 33; 510k clearances are up 5% to 3,244.
Source: FDA Regulatory Analysis (2007-2014), EvaluateMedTech World Preview 2015, Outlook to 2020, October 2015
10% of the global population to be 65+ by 2018.
ife expectancy is expected to increase from an estimated 72.7 years in 2013 to 73.7 years by 2018, bringing the number of people globally, 580 million – 10% percent of the population to be over 65. 10% of the global population will be over 65 by 2018. 1 in every 4 Japanese, 5 Western Europeans, 10 Chinese.
Source: Overview and Outlook,” 2015 Global Life Sciences Outlook: Adapting in an Era of Transformation 2015, December 2014
Medtech industry could be seeing $100b in mergers for the year 2015.
The first half of the year 86 mergers and acquisitions happened in the medtech industry. While being an average number for the first half of the year, the value for the mergers that closed is $83b, which is already double the figure of $39b for 2014. Medtronic’s acquisition of Covidien contributed to $50b of the $83b of the first half of 2015.
Source: Mergers to hit $100b by year-end? 2015 Medtech Half-Year Review, July 2015.